Pfizer (NYSE:PFE) Shares Down 1.5% - Should You Sell?
Market Beat·- Pfizer shares fell 1.5% to $27.83 amid market developments, including litigation settlements and a race between new product pipelines and patent expirations. - The company reported second-quarter earnings of $0.77 per share on revenue of $15.03 billion, outperforming Wall Street consensus estimates. - Major institutional investors like Vanguard and BlackRock adjusted their stakes, while analysts maintained a consensus Hold rating with a target price of $28.28.Valneva (VALN) Q2 2026 Earnings Call Transcript
Motley Fool·- Valneva reported half year 2026 product sales of €64 million and reaffirmed its full-year product sales guidance of €135 million to €150 million. - The company posted a net loss of €63.3 million, impacted by non-recurring items including €9.7 million in IXCHIQ cancellation fees and a €4.5 million inventory impairment. - Partner Pfizer filed a regulatory application for their partnered Lyme disease vaccine candidate with the European Medicines Agency, with regulatory decisions anticipated within the next 12 months.